Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics (DE:4E2)
STUTTGART:4E2
RESEARCH TOOLSreports
Relmada Therapeutics (4E2) Stock Price & Analysis
0 Followers
4E2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.18 - €6.35
Previous Close€3.4
Volume0.00
Average Volume (3M)N/A
Market Cap
€103.91M
Enterprise Value€14.02M
Total Cash (Recent Filing)$96.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta-0.22
Next Earnings
May 09, 2024EPS Estimate
-€0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
€16.33Price Target Upside380.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Relmada Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
4.03% Other Institutional Investors
95.97% Public Companies and
Individual Investors
4E2 FAQ
What was Relmada Therapeutics’s price range in the past 12 months?
Relmada Therapeutics lowest stock price was €2.18 and its highest was €6.35 in the past 12 months.
What is Relmada Therapeutics’s market cap?
Currently, no data Available
When is Relmada Therapeutics’s upcoming earnings report date?
Relmada Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 6 days.
How were Relmada Therapeutics’s earnings last quarter?
Relmada Therapeutics released its earnings results on Mar 19, 2024. The company reported -€0.784 earnings per share for the quarter, missing the consensus estimate of -€0.775 by -€0.009.
Is Relmada Therapeutics overvalued?
According to Wall Street analysts Relmada Therapeutics’s price is currently Undervalued.
Does Relmada Therapeutics pay dividends?
Relmada Therapeutics does not currently pay dividends.
What is Relmada Therapeutics’s EPS estimate?
Relmada Therapeutics’s EPS estimate is -€0.79.
How many shares outstanding does Relmada Therapeutics have?
Currently, no data Available
What happened to Relmada Therapeutics’s price movement after its last earnings report?
Relmada Therapeutics reported an EPS of -€0.784 in its last earnings report, missing expectations of -€0.775. Following the earnings report the stock price went down -3.614%.
Which hedge fund is a major shareholder of Relmada Therapeutics?
Among the largest hedge funds holding Relmada Therapeutics’s share is Fortitude Family Office, LLC. It holds Relmada Therapeutics’s shares valued at 1K.
---
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€16.33 (380.35% Upside)
€16.33 (380.35% Upside)
Blogger Sentiment
Bullish
DE:4E2 Sentiment 66%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.66%
12-Months-Change
Fundamentals
Return on Equity
-87.51%
Trailing 12-Months
Asset Growth
-36.20%
Trailing 12-Months
Company Description
Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.
---
4E2 Earnings Call
Q4 2024
0:00 / 0:00
---
4E2 Stock 12 Months Forecast
Average Price Target
€16.33
▲(380.35% Upside)
Technical Analysis
Best Analysts Covering 4E2
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-35.19%
reiterated a buy rating 2 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -35.19% per trade.
---